CRA was retained by the claimant in an arbitration regarding the breach of a license agreement relating to pharmaceutical manufacturing technology. In addition to quantifying damages, the CRA team also provided opinions relating to the value of market exclusivity for pharmaceuticals and the relative value of the licensed patented and non-patented intellectual property at issue in the case. Dr. Sean Sheridan submitted two expert reports and provided testimony in deposition and at the arbitration hearing.
CRA consultants named top patent professionals in the 2025 IAM Patent 1000 rankings
14 CRA consultants were recognized as leading economic, financial, and licensing expert witnesses by Intellectual Asset Management (IAM). The IAM Patent 1000:...